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Background/Aims: The purpose of this study was to inves-
tigate the malignant potential of aberrant crypt foci (ACF) by 
measuring the multiplicity of crypts and lectin expression in 
the early and late stages of 1,2-dimethylhydrazine (DMH)-
induced colon carcinogenesis. Methods: Six-week-old Wistar 
rats were injected subcutaneously with DMH for 27 weeks. 
We classified ACF according to the number of crypts per 
ACF as a few crypts (≤3 crypts, FC ACF) or numerous crypts 
(≥4 crypts, NC ACF). Immunohistochemistry was used to 
evaluate lectin expression. Results: In the early stage, FC 
ACF (590/1,902, 31.0%) occurred more frequently than 
NC ACF (35/449, 7.8%); whereas in the late stage, NC ACF 
(176/449, 39.2%) occurred more frequently than FC ACF 
(324/1,902, 17.0%). The number of ACF peaked at 15 to 20 
weeks. The ratio of NC/FC ACF increased gradually during 
carcinogenesis. The expression of both UEA1 and PNA was 
higher in NC ACF than FC ACF. Lectin expression increased in 
the late stage compared with the early stage. Conclusions: 
The expression of lectin was higher in NC ACF and ACF in the 
late stage. Therefore, ACF with higher multiplicities in the late 
stage may have more malignant potential in DMH-induced 
colon carcinogenesis. (Gut Liver 2012;6:229-234)
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INTRODUCTION
Aberrant crypt foci (ACF) are thought to represent putative 
preneoplastic lesions or intermediate markers of colon carci-
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nogenesis in experimental animals and humans.
1-3 ACF are 
described as lesions comprising enlarged crypts that are slightly 
elevated above the surrounding mucosa and whose crypts stain 
densely with methylene blue. ACF often have a slit-shaped lu-
minal opening and an increased pericryptal space.
2-4 In experi-
mental animal models, colon carcinogens can induce various 
kinds of growth patterns, topographic features and numbers of 
ACF depending on the experimental protocol. ACF are highly 
heterogeneous in number and crypt multiplicity, and moreover, 
the sequential changes in ACF during carcinogenesis are de-
bated.
2,5-8
Many genetic markers including oncogenes such as K-ras 
and β-catenin have been used to show that ACF are precursors 
of colon cancer in animal studies.
9,10 Fetal-type differentiation 
markers such as mucin and plant lectin reappear during cancer 
development, and are regarded as good markers of precancerous 
lesions.
8,11 The outer surface of mammalian cells, including ma-
lignant cells contains a carbohydrate-rich coat, the glycocalyx. 
On the outside of the cell membrane, carbohydrate chains are 
covalently linked to lipids and proteins (so-called glycoconju-
gates). Glycoconjugates are involved in cell-to-cell and cell-
to-matrix interactions, which are important during malignant 
progression. Glycoconjugate abnormalities are found in epithe-
lial malignancies and precancerous lesions.
12 These changes in 
membrane glycosylation can be detected histochemically with 
labeled lectins such as Ulex europaeus agglutinin-I (UEA1) and 
peanut agglutinin (PNA).
11 However, there are few reports on 
lectin expression as a molecular marker of ACF.
The purpose of the current study was to evaluate the malig-
nant potential of ACF by observing the morphological sequen-230  Gut and Liver, Vol. 6, No. 2, April 2012




Six-week-old Wistar male rats weighing 100 to 120 g were 
used. The animals were handled according to the rules of labo-
ratory animals at The Catholic University of Korea, Seoul, Ko-
rea. 1,2-dimethylhydrazine (DMH) (Sigma Chemicals, St. Louis, 
MO, USA) was used to induce experimental colon cancer. DMH 
was prepared as a 0.5% solution in 0.2 mM ethylene diamine 
tetra acetic acid (EDTA) and adjusted to pH 6.5 with sodium 
bicarbonate. DMH was injected subcutaneously at a dose of 20 
mg/kg of body weight once a week for 27 weeks. Seven rats 
were sacrificed 5, 10, 15, 20, 25, and 30 weeks after the first 
DMH injection. As a normal control group, 6 rats were injected 
subcutaneously with EDTA/sodium bicarbonate according to the 
same schedule.
2. Detection of ACF
The colon was resected and washed gently with phosphate-
buffered saline (PBS). The resected colon was cut open longitu-
dinally, placed flat between filter papers, and fixed in 4% para-
formaldehyde for 2 hours. Fixed colons were stained with 0.2% 
methylene blue, and the number of ACF was counted under a 
microscope. ACF were identified as lesions comprising enlarged 
crypts with an increased pericryptal area having a slightly el-
evated appearance above the surrounding mucosa and higher 
intensity staining by methylene blue. The tissue was then em-
bedded in paraffin, sectioned at a thickness of 4 μm and stained 
with hematoxylin and eosin (H&E) (Fig. 1A). We classified ACF 
according to the number of crypts per ACF as few crypts (≤3 
crypts, FC ACF) or numerous crypts (≥4 crypts, NC ACF). 
3. Immunohistochemical analysis 
Paraffin-embedded tissues including ACF were sectioned at 
a thickness of 4 μm and placed on poly-L-lysine-coated slides. 
Paraffin sections were deparaffinized in xylene and dehydrated 
in serial graded ethanol solutions. Endogenous alkaline phos-
phatase activity was blocked with 20% acetic acid. After rinsing 
in PBS, the sections were treated with blocking serum for 20 
minutes, then incubated for 3 hours at room temperature with 
primary antibody PNA and UEA1 (diluted 1:50; Vector Labo-
ratories Inc., Burlingame, CA, USA). After rinsing in PBS, the 
sections were incubated for 30 minutes at room temperature 
with an ABC-alkaline phosphatase kit (Vector Laboratories Inc.). 
Finally, the reaction products were visualized using Fast-Red 
(Vector Laboratories Inc.), counterstained with Mayer hema-
toxylin, and dehydrated, cleared, and mounted. The staining 
intensity of UEA1 was scored as follows: 0, <10 cells; 1+, 10 
cells to 10% of goblet cells; 2+, 10% to 50% of goblet cells; and 
3+, >50% of goblet cells (Fig. 1B-E). The staining intensity of 
PNA was scored as follows: 0, no staining of goblet cell mucus; 
1+, individual goblet cells containing PNA-positive mucus; and 
2+, individual glands containing numerous PNA-positive goblet 
cells (Fig. 1F-H).
4. Statistical analysis
The number of ACF is expressed as the mean and standard 
deviation. Conventional Student’s t-test were used to evaluate 
significant differences for continuous variables between two 
groups. All statistical analyses were performed using SPSS ver-
sion 15.0 (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was 
considered statistically significant. Asterisk in the figures indi-
cate significant differences between two groups.
Fig. 1. Ulex europaeus agglutinin-I (UEA1) and peanut agglutinin (PNA) expression determined by immunohistochemistry in aberrant crypt foci 
(ACF) (×200). (A) H&E staining of ACF. (B-E) Expression of UEA1 in ACF according to staining intensity (0, 1+, 2+ and 3+, respectively). (F-H) 
Expression of PNA in ACF according to staining intensity (0, 1+ and 2+, respectively).Won HS, et al: Sequential Changes in Aberrant Crypt Foci  231
RESULTS
1. Induction of ACF according to time sequence
In the experimental group, mucosal edema and hemorrhage 
became worse with repeated administration of DMH. Adenomas 
were observed at 20 weeks after the administration of DMH. 
Nonmucinous adenocarcinomas were first observed at 25 weeks, 
and mucinous adenocarcinomas developed at 30 weeks after the 
administration of DMH. In the control group, mucosal edema, 
hemorrhage, and atrophy were not observed, and there were no 
ACF or adenocarcinomas. The number of ACF stratified by crypt 
multiplicity according to time sequence are summarized in Ta-
ble 1. During DMH-induced colon carcinogenesis, a total of 2,351 
ACF developed; more were FC ACF (1,902) than NC ACF (449). 
In the early stage (5 to 10 weeks), FC ACF (590, 31.0%) were 
developed relatively more frequently than NC ACF (35, 7.8%). 
In the late stage (25 to 30 weeks), NC ACF (176, 39.2%) were 
occurred more frequently than FC ACF (324, 17.0%) (p=0.006).
The number of ACF was maximal at 15 to 20 weeks after 
the first carcinogen treatment, after which the number of ACF 
decreased gradually, irrespective of crypt multiplicity. However, 
the NC/FC ACF ratio increased progressively with time after 
DMH administration: 0 (0/278) at 5 weeks, 0.112 (35/312) at 10 
weeks, 0.151 (76/502) at 15 weeks, 0.333 (162/486) at 20 weeks, 
0.448 (117/261) at 25 weeks, and 0.936 (59/63) at 30 weeks (Fig. 
2).
2. Expression of UEA1 and PNA in ACF, adenomas, and ad-
enocarcinomas
UEA1 was not expressed in the colonic mucosa of the control 
group. PNA was weakly expressed in the Golgi apparatus of 
proximal colonic mucosal cells in some of the control group. 
Both UEA1 and PNA were overexpressed (score 2+ or 3+) in 
all adenomas and adenocarcinomas. The ratio of no staining 
(score 0) to strong staining intensity (UEA1 score 3+; PNA score 
2+) ACF according to time sequence was shown in Fig. 3. The 
expression of UEA1 and PNA was progressively increased over 
time. 
The expression of UEA1 increased in the late stage than in 
the early stage. In the early stage (5 to 10 weeks), UEA1 was 
expressed in the total ACF, FC ACF, and NC ACF as follows: 
staining intensity 0, 375 (60.0%), 370 (62.7%), 5 (14.3%); stain-
ing intensity 1+, 113 (18.1%), 106 (18.0%), 7 (20.0%); staining 
intensity 2+, 91 (14.6%), 70 (11.9%), 21 (60.0%); and staining 
intensity 3+, 46 (7.3%), 44 (7.4%), 2 (5.7%). The respective val-
ues in the late stage (25 to 30 weeks) were: staining intensity 0, 
7 (1.4%), 7 (2.2%), 0; staining intensity 1+, 4 (0.8%), 4 (1.2%), 0; 
staining intensity 2+, 28 (5.6%), 25 (7.7%), 3 (1.7%); and stain-
ing intensity 3+, 462 (92.2%), 288 (88.9%), 174 (98.3%) (p<0.001, 
Fig. 4). 
The expression of PNA also increased with time and in rela-
tion to the number of crypts. In the early stage (5 to 10 weeks), 
PNA was expressed in the total ACF, FC ACF, and NC ACF 
as follows: staining intensity 0, 541 (85.3%), 538 (89.8%), 3 
(8.6%); staining intensity 1+, 74 (11.7%), 46 (7.7%), 28 (80.0%); 
and staining intensity 2+, 19 (3.0%), 15 (2.5%), 4 (11.4%). The 
respective values in the late stage (25 to 30 weeks) were; stain-
ing intensity 0, 205 (40.9%), 159 (49.1%), 46 (26.0%); staining 
Table 1. The Number of ACF according to Time Sequence in DMH-
Induced Rat Colon Carcinogenesis
Time, wk ACF with ≤3 crypts ACF with ≥4 crypts  p-value
  5 39.71±25.52 0 0.006
10 44.57±15.75 5.00±2.58 0.001
15 71.71±25.14 10.86±6.60 0.001
20 68.57±24.51 21.57±13.97 0.001
25 37.28±14.99 13.86±5.79 0.005
30 9.00±6.90 8.42±3.64 0.851
Data are presented as mean±SD. 
ACF, aberrant crypt foci; DMH, 1,2-dimethylhydrazine.
Fig. 2. The ratio of numerous crypts (NC) aberrant crypt foci (ACF) to 
few crypts (FC) ACF according to the time sequence after 1,2-dimeth-
ylhydrazine administration. 
Fig. 3. The ratio of no staining to strong staining intensity aberrant 
crypt foci (ACF) according to time sequence after 1,2-dimethylhydra-
zine administration.
UEA1, Ulex europaeus agglutinin-I; PNA, peanut agglutinin.232  Gut and Liver, Vol. 6, No. 2, April 2012
intensity 1+, 207 (41.3%), 114 (35.2%), 93 (52.5%); staining 
intensity 2+, 89 (17.8%), 51 (15.7%), 38 (21.5%) (p<0.001, Fig. 5). 
DISCUSSION
In this study, using lectin expression, we intended to deter-
mine the malignant potential of ACF occurred during DMH-
induced colon carcinogenesis. The DMH model of colon carci-
nogenesis is a valid, widely used model of experimental colon 
carcinogenesis. In most protocols of DMH-induced colon car-
cinogenesis, ACF or colonic tumors were confirmed at 8 to 12 
weeks after application (short-term study) or at 40 weeks later 
(long-term study).
13 Therefore, we defined early stage as 5 to 10 
weeks and late stage as 25 to 30 weeks, and compared the ACF 
in the early and late stage. 
A total of 2,351 ACF with 35 adenocarcinomas developed 
within 30 weeks after DMH administration. FC ACF developed 
more frequently than NC ACF during carcinogenesis. FC ACF 
developed relatively more in the early stage compared to NC 
ACF, whereas vice versa in the late stage. These findings are 
consistent with the results of several previous reports show-
ing that repeated administration of a carcinogen increases the 
number of ACF with multiple crypts.
3,7,10 In our study, about a 
quarter of NC ACF occurred relatively early, at 10 to 15 weeks, 
but this proportion is not large compared to FC ACF occurred at 
the same time. ACF develop as early as 2 to 4 weeks after car-
cinogen administration, and ACF are a heterogeneous group of 
lesions.
14 Most of ACF show a hyperplastic character, while only 
a small group of ACF may progress to ACF with dysplasia.
13 NC 
ACF does not necessarily mean ACF with dysplasia, therefore, 
some of NC ACF will probably develop early. 
Meanwhile, the number of NC ACF was maximal at 20 weeks 
Fig. 4. Ulex europaeus agglutinin-I expression in (A) total aberrant crypt foci (ACF), (B) ACF with ≤3 crypts, and (C) ACF with ≥4 crypts in the 
early and late stages of carcinogenesis. 
*Indicate significant differences between two groups (p<0.05).
Fig. 5. Peanut agglutinin expression in (A) total aberrant crypt foci (ACF), (B) ACF with ≤3 crypts, and (C) ACF with ≥4 crypts in the early and late 
stages of carcinogenesis. 
*Indicate significant differences between two groups (p<0.05).Won HS, et al: Sequential Changes in Aberrant Crypt Foci  233
after DMH injection and then decreased. It may be due to 
changes of some of ACF during the multistep process of colon 
carcinogenesis. We found colon adenoma first at 20 weeks, as 
in other reports.
3,8 Some selected ACF may progress to adenoma 
or adenocarcinoma.
13,15,16 Also, some ACF may be regressed by 
apoptosis or restored to the normal crypts during the process.
4 
Therefore, the number of ACF can be reduced in the late stage. 
We assessed the NC/FC ACF ratio according to time sequence. 
It tended to increase gradually through the course of carcino-
genesis. These results suggest that the number of crypts in the 
ACF is a more important factor for identifying the development 
of malignancy than the total number of ACF. It was consistent 
with previous findings.
13 Further studies are warranted to verify 
the NC/FC ACF ratio as a predictive marker of colon malignan-
cy. 
We measured the lectin expression of ACF to evaluate their 
malignant potential because the lectin-binding capacity to a cell 
is a well-known marker of malignancy.
11,12 Lectins are carbo-
hydrate-binding proteins of nonimmune origin that agglutinate 
cells and/or precipitate polysaccharides or glycoconjugates.
17,18 
Lectin UEA1 is a combined glycoprotein containing α-1 fu-
cosyl residue, which binds to neoplastic cells but is incapable of 
binding to cell surface glycoconjugates in most nonneoplastic 
mucosal cells.
19 In breast cancer, tumors with binding sites for 
UEA1 are associated with poor prognosis.
20 In the present study, 
the expression of UEA1 was higher in NC ACF than in FC ACF. 
Therefore, ACF with high multiplicity have a higher capacity for 
malignant progression than do ACF with low multiplicity. The 
expression of UEA1 was also higher in ACF appearing in the 
late stage than those appearing in the early stage, irrespective of 
ACF multiplicity. These findings suggest that ACF found in the 
late stage may be more likely to progress into malignant lesions 
than ACF found in the early stage. 
Alterations in cell surface carbohydrate on colon cancer cells 
include neoexpression of O-linked core carbohydrate antigens.
21 
The typical antigen is the Thomsen-Friedenreich (TF) oncofetal 
carbohydrate antigen of O-linked oligosaccharide chains on 
glycoproteins. This antigen is expressed in the neonatal colon 
but is normally masked by further glycosylation or sulfation in 
the adult colon.
21 The expression of TF antigen increases in hy-
perplastic and adenomatous colonic polyps, and in colon can-
cer.
15,22 TF antigen is detected by the lectin PNA, suggesting that 
PNA together with UEA1 might be useful molecular markers for 
predicting tumorigenic potential. In our study, the expression 
of both UEA1 and PNA was higher in NC ACF than in FC ACF, 
and in ACF found in the late stage than in the early stage. 
In conclusion, lectin expression, including UEA1 and PNA, 
was higher in NC ACF and ACF in the late stage. These findings 
suggest that either ACF constituting a number of crypts or ACF 
found in a later stage may have higher malignant potential in 
DMH-induced colon carcinogenesis. Therefore, ACF with higher 
crypt multiplicities may be considered to be a valid biomarker 
in colon carcinogenesis.
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